Xeris Biopharma Holdings, Inc.
Financials
Valuation Metrics
Xeris Biopharma Holdings, Inc.'s Market Cap is $1.95B. At end of 2025 it was $1.30B. Ranked #2000 of 3,116 in US market (top 64%), #757 of 1,472 on NASDAQ (top 51%), #142 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.95B | US#2,000/3,116 Sec#142/265 |
| Revenue | $335M | US#2,386/3,116 Sec#90/265 |
| Net Income | $-17M | US—/3,116 Sec—/265 |
| Total Assets | $412M | US#2,827/3,116 Sec#181/265 |
| Net Assets | $-10M | US#2,914/3,116 Sec#240/265 |
| Employees | 435 | US#2,304/3,116 Sec#85/265 |
| Value | ||
| P/S | 5.82x | US#2,399/3,116 Sec#88/265 |
| EV/EBITDA | 129.19x | US#2,443/3,116 Sec#81/265 |
| FCF Yield | 2.84% | US#1,845/3,116 Sec#57/265 |
| Profitability | ||
| ROA | -4.17% | US#2,488/3,116 Sec#84/265 |
| Op. Margin | 10.91% | US#1,497/3,116 Sec#61/265 |
| Revenue Growth | 36.33% | US#335/3,116 Sec#53/265 |
| Financial Health | ||
| Total Debt | $289M | US#2,100/3,116 Sec#80/265 |
| FCF | $55M | US#1,943/3,116 Sec#69/265 |
| Cash | $122M | US#2,084/3,116 Sec#154/265 |
| Current Ratio | 1.45x | US#1,708/3,116 Sec#237/265 |
| Net Debt/EBITDA | 10.22x | US#2,360/3,116 Sec#83/265 |
| Performance | ||
| 1Y Return | 10.30% | US#1,443/3,116 Sec#124/265 |
| 1M Return | 12.03% | US#956/3,116 Sec#65/265 |
| From 52W High | -6.22% | US#545/3,116 Sec#39/265 |
| 1Y MDD | -46.57% | US#2,249/3,116 Sec#148/265 |
| Trading | ||
| Volume | 1,524,391 shares | US#1,027/3,116 Sec#101/265 |
| Trading Value | $16M | US#1,936/3,116 Sec#149/265 |
| Per Share | ||
| EPS | $-0.09 | US—/3,116 Sec—/265 |
| BPS | $-0.05 | US—/3,116 Sec—/265 |
Company Info
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.